You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Authors’ response: Importance of defining loss of response before therapeutic drug monitoring

https://doi.org/10.1136/gutjnl-2014-309044

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors CS drafted the Letter. Both authors approved the letter.

    • Funding This research received no specific funding. Support for this study was provided by unrestricted grants from Aase and Ejnar Danielsen's Foundation, Beckett Foundation, Danish Biotechnology Program, Danish Colitis-Crohn Society, Danish Medical Association Research Foundation, Frode V. Nyegaard and Wife's Foundation, Health Science Research Foundation of Region of Copenhagen, Herlev Hospital Research Council, Lundbeck Foundation, P. Carl Petersen's Foundation, Ole Østergaard Thomsen’s Research Foundation, and Jørn Brynskov’s Research Foundation.

    • Competing interests CS has served as speaker for MSD, Abbvie and Pfizer, and as a consultant for MSD and Takeda Pharmaceutical Company.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles